CNS Drugs

, Volume 16, Issue 7, pp 445–455 | Cite as

Cognitive Dysfunction in Multiple Sclerosis

Natural History, Pathophysiology and Management
  • Bridget Bagert
  • Patricia Camplair
  • Dennis Bourdette
Therapy in Practice

Abstract

Cognitive dysfunction is a major cause of disability in patients with multiple sclerosis (MS). The prevalence of cognitive dysfunction is estimated at 45 to 65%. Natural history studies suggest that once cognitive dysfunction develops in a patient with MS, it is not likely to remit. Unlike physical disability in MS, cognitive disability correlates weakly with T2 lesion burden on brain magnetic resonance imaging (MRI). More robust correlations exist with magnetisation transfer imaging and MRI measures of brain atrophy. Patients with MS who have cognitive impairment most commonly display deficits in the cognitive domains of memory, learning, attention and information processing.

In diagnosing cognitive dysfunction in a patient with MS, it is important first to recognise and treat the common comorbidities of fatigue and depression. The first step in the treatment of cognitive dysfunction is to delay disease progression, and there are currently five such disease-modifying agents approved for the treatment of MS (two preparations of interferon-β-1a, interferon-β-1b, glatiramer acetate and mitoxantrone). Nonpharmacological measures, such as cognitive rehabilitation, occupational therapy and psychotherapy, are the mainstays of symptomatic treatment. Pharmacological symptomatic therapy centres on the treatment of comorbid fatigue and depression. There are currently no effective pharmacological agents approved as symptomatic therapy of cognitive dysfunction in MS.

References

  1. 1.
    Rao SM. Neuropsychology of multiple sclerosis. Curr Opin Neurol 1995; 8(3): 216–20PubMedCrossRefGoogle Scholar
  2. 2.
    Rao SM, Leo GL, Ellington L, et al. Cognitive dysfunction in multiple sclerosis: II: impact on employment and social functioning. Neurology 1991; 41(5): 692–6PubMedCrossRefGoogle Scholar
  3. 3.
    Amato MP, Ponziani G, Siracusa G, et al. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 2001; 58(10): 1602–6PubMedCrossRefGoogle Scholar
  4. 4.
    Schultheis MT, Garay E, DeLuca J. The influence of cognitive impairment on driving performance in multiple sclerosis. Neurology 2001; 56(8): 1089–94PubMedCrossRefGoogle Scholar
  5. 5.
    Whitaker JN, McFarland HF, Rudge P, et al. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler 1995; 1(1): 37–47PubMedGoogle Scholar
  6. 6.
    Beatty WW, Goodkin DE. Screening for cognitive impairment in multiple sclerosis: an evaluation of the Mini-Mental State Examination. Arch Neurol 1990; 47(3): 297–301PubMedCrossRefGoogle Scholar
  7. 7.
    Amato MP, Ponziani G, Pracucci G, et al. Cognitive impairment in early-onset multiple sclerosis: pattern, predictors, and impact on everyday life in a 4-year follow-up. Arch Neurol 1995; 52(2): 168–72PubMedCrossRefGoogle Scholar
  8. 8.
    Jennekens-Schinkel A, Laboyrie PM, Lanser JB, et al. Cognition in patients with multiple sclerosis after four years. J Neurol Sci 1990; 99(2–3): 229–47PubMedCrossRefGoogle Scholar
  9. 9.
    Kujala P, Portin R, Ruutiainen J. The progress of cognitive decline in multiple sclerosis: a controlled 3-year follow-up. Brain 1997; 120 (Pt 2): 289–97PubMedCrossRefGoogle Scholar
  10. 10.
    Foong J, Rozewicz L, Quaghebeur G, et al. Neuropsychological deficits in multiple sclerosis after acute relapse. J Neurol Neurosurg Psychiatry 1998; 64(4): 529–32PubMedCrossRefGoogle Scholar
  11. 11.
    Heaton RK, Nelson LM, Thompson DS, et al. Neuropsychological findings in relapsing-remitting and chronic-progressive multiple sclerosis. J Consult Clin Psychol 1985; 53(1): 103–10PubMedCrossRefGoogle Scholar
  12. 12.
    Feinstein A, Kartsounis LD, Miller DH, et al. Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and MRI follow up study. J Neurol Neurosurg Psychiatry 1992; 55(10): 869–76PubMedCrossRefGoogle Scholar
  13. 13.
    Comi G, Filippi M, Martinelli V, et al. Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. J Neurol Sci 1995; 132(2): 222–7PubMedCrossRefGoogle Scholar
  14. 14.
    Prineas J, McDonold WI. Demyelinating diseases. In: Graham D, Lantos P, editors. Greenfield’s neuropathology. London: Arnold, 1997: 815–42Google Scholar
  15. 15.
    Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338(5): 278–85PubMedCrossRefGoogle Scholar
  16. 16.
    Kidd D, Barkhof F, McConnell R, et al. Cortical lesions in multiple sclerosis. Brain 1999; 122 (Pt 1): 17–26PubMedCrossRefGoogle Scholar
  17. 17.
    Ge Y, Grossman RI, Udupa JK, et al. Magnetization transfer ratio histogram analysis of gray matter in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2001; 22(3): 470–5PubMedGoogle Scholar
  18. 18.
    Rovaris M, Filippi M, Falautano M, et al. Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology 1998; 50(6): 1601–8PubMedCrossRefGoogle Scholar
  19. 19.
    van Buchem MA, Grossman RI, Armstrong C, et al. Correlation of volumetric magnetization transfer imaging with clinical data in MS. Neurology 1998; 50(6): 1609–17PubMedCrossRefGoogle Scholar
  20. 20.
    Edwards SG, Liu C, Blumhardt LD. Cognitive correlates of supratentorial atrophy on MRI in multiple sclerosis. Acta Neurol Scand 2001; 104(4): 214–23PubMedCrossRefGoogle Scholar
  21. 21.
    Filippi M, Tortorella C, Rovaris M, et al. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68(2): 157–61PubMedCrossRefGoogle Scholar
  22. 22.
    Rovaris M, Filippi M. MRI correlates of cognitive dysfunction in multiple sclerosis patients. J Neurovirol 2000; 6Suppl. 2: S172–5PubMedGoogle Scholar
  23. 23.
    Camp SJ, Stevenson VL, Thompson AJ, et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Brain 1999; 122 (Pt 7): 1341–8PubMedCrossRefGoogle Scholar
  24. 24.
    Fulton JC, Grossman RI, Udupa J, et al. MR lesion load and cognitive function in patients with relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 1999; 20(10): 1951–5PubMedGoogle Scholar
  25. 25.
    Zivadinov R, Sepcic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 70(6): 773–80PubMedCrossRefGoogle Scholar
  26. 26.
    Brassington JC, Marsh NV. Neuropsychological aspects of multiple sclerosis. Neuropsychol Rev 1998; 8(2): 43–77PubMedCrossRefGoogle Scholar
  27. 27.
    Rao SM, Leo GL, Bernardin L, et al. Cognitive dysfunction in multiple sclerosis: I: frequency, patterns, and prediction. Neurology 1991; 41(5): 685–91PubMedCrossRefGoogle Scholar
  28. 28.
    Wishart H, Sharpe D. Neuropsychological aspects of multiple sclerosis: a quantitative review. J Clin Exp Neuropsychol 1997; 19(6): 810–24PubMedCrossRefGoogle Scholar
  29. 29.
    Thornton AE, Raz N. Memory impairment in multiple sclerosis: a quantitative review. Neuropsychology 1997; 11(3): 357–66PubMedCrossRefGoogle Scholar
  30. 30.
    Rao SM. Multiple sclerosis. In: Cummings JL, editor. Subcortical dementia. New York: Oxford University Press, 1990: 164–180Google Scholar
  31. 31.
    Rao SM. Neuropsychology of multiple sclerosis: a critical review. J Clin Exp Neuropsychol 1986; 8(5): 503–42PubMedCrossRefGoogle Scholar
  32. 32.
    Rao SM, Grafman J, DiGiulio D, et al. Memory dysfunction in multiple sclerosis: its relation to working memory, semantic encoding, and implicit memory. Neuropsychology 1993; 7: 364–74CrossRefGoogle Scholar
  33. 33.
    Penman MF. Assessing the prevalence of cognitive impairment in multiple sclerosis: implications for patient management. Axone 1991; 13(2): 45–9PubMedGoogle Scholar
  34. 34.
    Grafman JH. Disorders of memory. In: Rao S, editor. Neuro-behavioral aspects of multiple sclerosis. New York: Oxford University Press, 1990: 102–77Google Scholar
  35. 35.
    DeLuca J, Barbieri-Berger S, Johnson SK. The nature of memory impairments in multiple sclerosis: acquisition versus retrieval. J Clin Exp Neuropsychol 1994; 16(2): 183–9PubMedCrossRefGoogle Scholar
  36. 36.
    DeLuca J, Gaudino EA, Diamond BJ, et al. Acquisition and storage deficits in multiple sclerosis. J Clin Exp Neuropsychol 1998; 20(3): 376–90PubMedCrossRefGoogle Scholar
  37. 37.
    Demaree HA, Gaudino EA, DeLuca J, et al. Learning impairment is associated with recall ability in multiple sclerosis. J Clin Exp Neuropsychol 2000; 22(6): 865–73PubMedCrossRefGoogle Scholar
  38. 38.
    Bravin JH, Kinsella GJ, Ong B, et al. A study of performance of delayed intentions in multiple sclerosis. J Clin Exp Neuropsychol 2000; 22(3): 418–29PubMedCrossRefGoogle Scholar
  39. 39.
    Archibald CJ, Fisk JD. Information processing efficiency in patients with multiple sclerosis. J Clin Exp Neuropsychol 2000; 22(5): 686–701PubMedCrossRefGoogle Scholar
  40. 40.
    Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis: Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000; 48(6): 885–92PubMedCrossRefGoogle Scholar
  41. 41.
    Krupp LB, Alvarez LA, LaRocca NG, et al. Fatigue in multiple sclerosis. Arch Neurol 1988; 45(4): 435–7PubMedCrossRefGoogle Scholar
  42. 42.
    Johnson SK, Lange G, DeLuca J. The effects of fatigue on neuropsychological performance in patients with chronic fatigue syndrome, multiple sclerosis, and depression. Appl Neuropsychol 1997; (3): 145-53Google Scholar
  43. 43.
    Paul RH, Beatty WW, Schneider R. Cognitive and physical fatigue in multiple sclerosis: relations between self-report and objective performance. Appl Neuropsychol 1998;5(3): 143–8PubMedCrossRefGoogle Scholar
  44. 44.
    Elkins LE, Pollina DA, Scheffer SR, et al. Effects of fatigue on cognitive functioning in multiple sclerosis [abstract]. Neurology 1998; 50: A126Google Scholar
  45. 45.
    Minden SL, Schiffer RB. Affective disorders in multiple sclerosis: review and recommendations for clinical research. Arch Neurol 1990; 47(1): 98–104PubMedCrossRefGoogle Scholar
  46. 46.
    Arnett PA, Higginson CI, Voss WD, et al. Depressed mood in multiple sclerosis: relationship to capacity-demanding memory and attentional functioning. Neuropsychology 1999; 13(3): 434–46PubMedCrossRefGoogle Scholar
  47. 47.
    Rao SM, Leo GJ, St Aubin-Faubert P. On the nature of memory disturbance in multiple sclerosis. J Clin Exp Neuropsychol 1989; 11(5): 699–712PubMedCrossRefGoogle Scholar
  48. 48.
    Minden SL, Moes EJ, Orav J, et al. Memory impairment in multiple sclerosis. J Clin Exp Neuropsychol 1990; 12(4): 566–86PubMedCrossRefGoogle Scholar
  49. 49.
    Basso MR, Beason-Hazen S, Lynn J, et al. Screening for cognitive dysfunction in multiple sclerosis. Arch Neurol 1996; 53(10): 980–4PubMedCrossRefGoogle Scholar
  50. 50.
    Fischer JS. Assessment of neuropsychological function. In: Rudick R, editor. Multiple sclerosis therapeutics. London: Martin Dunitz, 1999: 31–47Google Scholar
  51. 51.
    Comi G, Filippi M, Wolinsky JS. European/Canadian multi-center, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging—measured disease activity and burden in patients with relapsing multiple sclerosis: European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49(3): 290–7PubMedCrossRefGoogle Scholar
  52. 52.
    Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial: the Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45(7): 1268–76PubMedCrossRefGoogle Scholar
  53. 53.
    Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial: the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43 (4): 655-61Google Scholar
  54. 54.
    Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39(3): 285–94PubMedCrossRefGoogle Scholar
  55. 55.
    Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62(2): 112–8PubMedCrossRefGoogle Scholar
  56. 56.
    Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis: PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352 (9139): 1498-504Google Scholar
  57. 57.
    Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53(8): 1698–704PubMedCrossRefGoogle Scholar
  58. 58.
    Pliskin NH, Hamer DP, Goldstein DS, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996; 47(6): 1463–8PubMedCrossRefGoogle Scholar
  59. 59.
    Weinstein A, Schwid SI, Schiffer RB, et al. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999; 56(3): 319–24PubMedCrossRefGoogle Scholar
  60. 60.
    LaRocca NG, Kalb RC. Efficacy of rehabilitation in multiple sclerosis. J Neurol Rehabil 1992; 6: 147–55Google Scholar
  61. 61.
    Jonsson A, Korfitzen EM, Heltberg A, et al. Effects of neuropsychological treatment in patients with multiple sclerosis. Acta Neurol Scand 1993; 88(6): 394–400PubMedCrossRefGoogle Scholar
  62. 62.
    Foley FW, Dince WM, Bedell JR, et al. Psychoremediation of communication skills for cognitively impaired persons with multiple sclerosis. J Neurol Rehabil 1994; 8(4): 165–76Google Scholar
  63. 63.
    Rodgers D, Khoo K, MacEachen M, et al. Cognitive therapy for multiple sclerosis: a preliminary study. Altern Ther Health Med 1996; 2(5): 70–4PubMedGoogle Scholar
  64. 64.
    Plohmann AM, Kappos L, Ammann W, et al. Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64(4): 455–62PubMedCrossRefGoogle Scholar
  65. 65.
    Greene YM, Tariot PN, Wishart H, et al. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol 2000; 20(3): 350–6PubMedCrossRefGoogle Scholar
  66. 66.
    Rorie KD, Stump DA, Jeffrey DR. Effects of donepezil on cognitive function in patients with multiple sclerosis [abstract]. Neurology 2001; 56 Suppl. 3: A99Google Scholar
  67. 67.
    Oken BS, Storzbach DM, Kaye JA. The efficacy of ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998; 55(11): 1409–15PubMedCrossRefGoogle Scholar
  68. 68.
    Geisler MW, Sliwinski M, Coyle PK, et al. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 1996. 53(2): 185–8PubMedCrossRefGoogle Scholar

Copyright information

© 2002 2002

Authors and Affiliations

  • Bridget Bagert
    • 1
    • 2
  • Patricia Camplair
    • 2
  • Dennis Bourdette
    • 1
    • 2
  1. 1.Department of Veterans Affairs Medical CenterResearch and Neurology ServicesPortlandUSA
  2. 2.Department of NeurologyOregon Health & Science UniversityPortland, L-226USA

Personalised recommendations